Trial of MRSA Polymerase Chain Reaction for Pneumonia

NACompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

February 28, 2017

Study Completion Date

May 3, 2019

Conditions
PneumoniaMethicillin-Resistant Staphylococcus Aureus
Interventions
OTHER

Polymerase Chain Reaction (PCR)

Respiratory samples called bronchoalveolar lavage (BAL) gathered from subjects in the PCR arm will be tested for the presence of MRSA using the Cepheid Xpert® Assay. Xpert® is a qualitative in vitro test designed for rapid detection and differentiation of Staphylococcus aureus (SA) and methicillin resistant Staphylococcus aureus (MRSA) using PCR amplification. MRSA is identified by the mecA gene and staphylococcal cassette chromosome mec (SCCmec). Xpert® Assay is approved by the Federal Drug Administration to detect MRSA in soft tissue samples. Once the PCR is completed, the results will be relayed to the treating physician, and antibiotic therapy (vancomycin or linezolid) will be started or stopped based on the study protocol. All BAL samples will be sent for routine bacterial cultures.

Trial Locations (1)

60611

Northwestern Memorial Hospital, Chicago

All Listed Sponsors
lead

Northwestern University

OTHER

NCT02660554 - Trial of MRSA Polymerase Chain Reaction for Pneumonia | Biotech Hunter | Biotech Hunter